TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aziyo Biologics ( (ELUT) ) has shared an announcement.
On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative equity. Positive earnings call guidance and product growth provide some optimism, but valuation concerns and technical neutrality limit the score.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Average Trading Volume: 25,443
Technical Sentiment Signal: Sell
Current Market Cap: $83.05M
Learn more about ELUT stock on TipRanks’ Stock Analysis page.